Harvest One retail strategy to be released in the coming weeks after deal signed with Ontario

Harvest One CEO Grant Froese last month said that the company’s retail strategy would be announced in “the coming weeks, after subsidiary United Greeneries penned a deal to supply its Royal Highbranded cannabis to the Ontario government.

In August, the company’s Swiss subsidiary Satipharm announced favourable results of a clinical trial for an new epilepsy drug.

 

Children with treatment-resistant epilepsy saw an 82% reduction in monthly seizures while taking – alongside their regular medications – Satipharm’s CBD capsule.

The results of the clinical trial compared favourably to those published by GW Pharmaceuticals in its ground-breaking study, said Satipharm’s principal investigator Prof. Uri Kramer, director of Pediatric Epilepsy Service at Tel Aviv Sourasky Medical Center.

GW has already received FDA approval for its CBD drug Epidiolex and expects it to be on the market by the end of 2018. 

The study was conducted by Israeli-based PhytoTech Therapeutics

Harvest One is to acquire PhytoTech Limited, pending TSXV approval. approval and MMJ shareholder approval on September 28.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s